Alzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F24%3A10483171" target="_blank" >RIV/00216208:11110/24:10483171 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00064165:_____/24:10483171
Výsledek na webu
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=OAO7kb0vOM" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=OAO7kb0vOM</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.pnpbp.2024.111069" target="_blank" >10.1016/j.pnpbp.2024.111069</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Alzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates
Popis výsledku v původním jazyce
The strategy for the development of new drugs for Alzheimer's disease (AD) recognizes that an effective therapy requires early therapeutic intervention and a multifactorial approach that considers the individual initiators of AD development. Current knowledge of AD includes the understanding of pathophysiology, risk factors, biomarkers, and the evolving patterns of biomarker abnormalities. This knowledge is essential in identifying potential molecular targets for new drug development. This review summarizes promising AD drug candidates, many of which are currently in phase 2 or 3 clinical trials. New agents are classified according to the Common Alzheimer's Disease Research Ontology (CADRO). The main targets of new drugs for AD are processes related to amyloid beta and tau neurotoxicity, neurotransmission, inflammation, metabolism and bioenergetics, synaptic plasticity, and oxidative stress. These interventions are aimed at preventing disease onset and slowing or eliminating disease progression. The efficacy of pharmacotherapy may be enhanced by combining these drugs with other treatments, antioxidants, and dietary supplements. Ongoing research into AD pathophysiology, risk factors, biomarkers, and the dynamics of biomarker abnormalities may contribute to the understanding of AD and offer hope for effective therapeutic strategies in the near future.
Název v anglickém jazyce
Alzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates
Popis výsledku anglicky
The strategy for the development of new drugs for Alzheimer's disease (AD) recognizes that an effective therapy requires early therapeutic intervention and a multifactorial approach that considers the individual initiators of AD development. Current knowledge of AD includes the understanding of pathophysiology, risk factors, biomarkers, and the evolving patterns of biomarker abnormalities. This knowledge is essential in identifying potential molecular targets for new drug development. This review summarizes promising AD drug candidates, many of which are currently in phase 2 or 3 clinical trials. New agents are classified according to the Common Alzheimer's Disease Research Ontology (CADRO). The main targets of new drugs for AD are processes related to amyloid beta and tau neurotoxicity, neurotransmission, inflammation, metabolism and bioenergetics, synaptic plasticity, and oxidative stress. These interventions are aimed at preventing disease onset and slowing or eliminating disease progression. The efficacy of pharmacotherapy may be enhanced by combining these drugs with other treatments, antioxidants, and dietary supplements. Ongoing research into AD pathophysiology, risk factors, biomarkers, and the dynamics of biomarker abnormalities may contribute to the understanding of AD and offer hope for effective therapeutic strategies in the near future.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30215 - Psychiatry
Návaznosti výsledku
Projekt
<a href="/cs/project/NU23-04-00032" target="_blank" >NU23-04-00032: Mitochondriální toxicita oligomerů tau proteinu a její regulace léky na Alzheimerovu chorobu</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2024
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Progress in Neuro-Psychopharmacology & Biological Psychiatry
ISSN
0278-5846
e-ISSN
1878-4216
Svazek periodika
134
Číslo periodika v rámci svazku
August
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
22
Strana od-do
111069
Kód UT WoS článku
001262103400001
EID výsledku v databázi Scopus
2-s2.0-85196794735